1. Recently a radomized trial of vinorelbine versus best supportive care in patients at 70
years of age or older demonstrated a definite improvement in overall survival rate and
quality of life with chemotherapy.
2. The role of combination therapy containing the platinum compound, which is the standard
therapy for the young patients is still vague.
3. Gemcitabine and carboplatin have favorable toxicity profile.